- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
HighVista Strategies LLC Raises Holdings in BridgeBio Pharma
The institutional investor increased its stake in the biopharmaceutical company by over 21% in the third quarter.
Mar. 16, 2026 at 11:07am
Got story updates? Submit your updates here. ›
HighVista Strategies LLC, an institutional investor, grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 21.4% during the 3rd quarter, according to a recent SEC filing. The firm now owns 81,959 shares of the company's stock, worth approximately $4.26 million at the end of the quarter.
Why it matters
BridgeBio Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers. The increase in HighVista's stake suggests the institutional investor sees potential in the company's pipeline and future prospects.
The details
According to the filing, HighVista Strategies purchased an additional 14,460 shares of BridgeBio Pharma during the third quarter, bringing its total holdings to 81,959 shares. This investment represents approximately 1.0% of HighVista's portfolio.
- HighVista Strategies LLC increased its position in BridgeBio Pharma during the 3rd quarter of 2026.
The players
HighVista Strategies LLC
An institutional investor and hedge fund that owns a 1.0% stake in BridgeBio Pharma.
BridgeBio Pharma, Inc.
A clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers.
The takeaway
HighVista Strategies' increased investment in BridgeBio Pharma suggests the institutional investor sees long-term potential in the biopharmaceutical company's pipeline and future growth prospects.
